Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 1571

Conference Videos 83

Conference Information 1

Conference Topics 1

Year

2024 1

2023 110

2022 150

2021 154

2020 103

2019 93

2018 96

2017 79

2016 76

2015 87

2014 59

2013 56

2012 52

2011 54

2010 61

2009 51

2008 44

2007 56

2006 52

2005 37

open ︾

Keywords

cancer 27

system 17

lung cancer 16

optimization 13

index system 10

Artificial intelligence 9

system engineering 9

Multi-agent system 8

breast cancer 8

cervical cancer 8

management 8

management system 8

simulation 8

Qian Xuesen 7

cancer therapy 7

public health 7

China 6

COVID-19 5

Cancer 5

open ︾

Search scope:

排序： Display mode:

Organoid Technology and Clinical Applications in Digestive System Cancer Review

Xiaofang Zhao, Youhai Jiang, Chunliang Liu, Minghui Hou, Hongyang Wang, Jing Fu

Engineering 2022, Volume 9, Issue 2, Pages 123-130 doi: 10.1016/j.eng.2021.04.017

Abstract:

Cancers of the digestive system (DS), including esophageal, gastric, colorectal, liver, and pancreaticCurrent cancer models cannot faithfully recapitulate the critical features of the original tumor, resultingMore advanced cancer models are in urgent need of pathogenesis exploration and anticancer medicine developmentthe general methods to generate human DS organoids and their applications as a novel model in basic cancer

Keywords： Organoid Digestive system cancer Precision medicine

HTML PDF Collect

Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination

Lei Huang,Aman Xu

Frontiers of Medicine 2017, Volume 11, Issue 1, Pages 20-31 doi: 10.1007/s11684-016-0493-4

Abstract:

To date, gastric carcinoma (GC) is one of the common and fatal digestive malignancies worldwide.

Keywords： gastrointestinal fluid gastric carcinoma biomarker diagnosis prognosis gastrectomy adverse events

HTML PDF Collect

Bioorthogonal chemistry based on-demand drug delivery system in cancer therapy

Frontiers of Chemical Science and Engineering 2023, Volume 17, Issue 4, Pages 483-489 doi: 10.1007/s11705-022-2227-2

Abstract: process, the bioorthogonal reaction that commonly contains the “bond formation” and “bond cleavage” systembioorthogonal reaction that tailoring the metabolic glycoengineering tactics to modified cells for cancerapplications, the complexities, potential pitfalls, and opportunities of bioorthogonal chemistry in future cancer

Keywords： bioorthogonal reaction cancer therapy metabolic glycoengineering bioorthogonal catalytic patch

HTML PDF Collect

salvia miltiorrhiza pretreatment on the CCK and VIP expression in hepatic ischemia-reperfusion-induced digestive

Zhi-Yong ZHANG, Xiao-Ping CHEN, Qi-Ping LU

Frontiers of Medicine 2010, Volume 4, Issue 3, Pages 317-322 doi: 10.1007/s11684-010-0035-4

Abstract: It is suggested that the digestive tract congestion injury caused by liver ischemia can upregulate the

Keywords： hepatic ischemia-reperfusion digestive tract congestion cholecystokinin vasoactive intestinal peptide

HTML PDF Collect

Identification of cancer gene fusions based on advanced analysis of the human genome or transcriptome

Lu Wang

Frontiers of Medicine 2013, Volume 7, Issue 3, Pages 280-289 doi: 10.1007/s11684-013-0265-3

Abstract: as microarray-based approaches, next-generation sequencing, and NanoString nCounter gene expression system

Keywords： gene fusion cancer microarray next-generation sequencing NanoString nCounter system

HTML PDF Collect

Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 942-942 doi: 10.1007/s11684-021-0876-z

HTML PDF Collect

Progress and challenges in RET-targeted cancer therapy

Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 207-219 doi: 10.1007/s11684-023-0985-y

Abstract: Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and inthyroid cancer, but also increasingly in various types of cancers at low rates.

Keywords： pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug

HTML PDF Collect

Epithelial-to-mesenchymal transition in cancer: complexity and opportunities

Yun Zhang, Robert A. Weinberg

Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 361-373 doi: 10.1007/s11684-018-0656-6

Abstract: termed the epithelial-to-mesenchymal transition (EMT) plays an important role in both development and cancerinvasiveness, drug-resistance and the ability to form metastases at distant organs, and thereby contribute to cancer

Keywords： epithelial-to-mesenchymal transition cancer metastasis cancer stem cell

HTML PDF Collect

Liao Zhuan: Experience in Clinical Transformation of Changhai digestive system (2019.8.16)

22 Apr 2021

Keywords：医学

Metformin for cancer prevention

Yonghua Yang

Frontiers of Medicine 2011, Volume 5, Issue 2, Pages 115-117 doi: 10.1007/s11684-011-0112-3

HTML PDF Collect

Orlistat induces ferroptosis-like cell death of lung cancer cells

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 922-932 doi: 10.1007/s11684-020-0804-7

Abstract: synthesis is involved in the progression and treatment resistance of many types of cancers, including lung cancer; however, targeting the lipogenetic pathways for cancer therapy remains an unmet clinical need.we tested the anticancer activity of orlistat, an FDA-approved anti-obesity drug, in human and mouse cancerand we found that orlistat, as a single agent, inhibited the proliferation and viabilities of lung cancerand other types of cancer.

Keywords： orlistat ferroptosis FAF2 lung cancer

HTML PDF Collect

Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance

Fung Zhao, Eric W.-F. Lam

Frontiers of Medicine 2012, Volume 6, Issue 4, Pages 376-380 doi: 10.1007/s11684-012-0228-0

Abstract:

The forkhead transcription factors FOXO and FOXM1 have pivotal roles in tumorigenesis and in mediating chemotherapy sensitivity and resistance. Recent research shows that the forkhead transcription factor FOXM1 is a direct transcriptional target repressed by the forkhead protein FOXO3a, a vital downstream effector of the PI3K-AKT-FOXO signaling pathway. Intriguingly, FOXM1 and FOXO3a also compete for binding to the same gene targets, which have a role in chemotherapeutic drug action and sensitivity. An understanding of the role and regulation of the FOXO-FOXM1 axis will impact directly on our knowledge of chemotherapeutic drug action and resistance in patients, and provide new insights into the design of novel therapeutic strategy and reliable biomarkers for prediction of drug sensitivity.

Keywords： FOXO3a FOXM1 transcription factor cancer drug resistance tumorigenesis

HTML PDF Collect

Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic

Frontiers of Medicine doi: 10.1007/s11684-023-1050-6

Abstract: Pancreatic cancer, notorious for its late diagnosis and aggressive progression, poses a substantial challengeThis review endeavors to furnish a holistic insight into pancreatic cancer, encompassing its epidemiologyand explore recent research advancements in precursor lesions and molecular subtypes of pancreatic cancerAdditionally, we highlight the development and application of multi-omics approaches in pancreatic cancerresearch and discuss the latest combinations of pancreatic cancer biomarkers and their efficacy.

Keywords： pancreatic cancer cancer screening single cell molecular alterations precancerous lesion therapy

HTML PDF Collect

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Frontiers of Medicine 2023, Volume 17, Issue 1, Pages 18-42 doi: 10.1007/s11684-022-0976-4

Abstract: With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC), expanding

Keywords： non-small cell lung cancer driver mutations treatment strategy resistant mechanism immune-checkpoint

HTML PDF Collect

Low-dose CT for lung cancer screening: opportunities and challenges

Hongbing Shen

Frontiers of Medicine 2018, Volume 12, Issue 1, Pages 116-121 doi: 10.1007/s11684-017-0600-1

Abstract:

Lung cancer is among the most frequently diagnosed cancers worldwide and the leading cause of cancerScreening for lung cancer coupled with earlier intervention has long been studied as an approach to mortalityOn the basis of this finding, LDCT has been recommended for lung cancer screening in high-risk populationsThis paper summarizes and discusses the main observations and challenges of LDCT screening for lung cancerComplementary biomarkers and technical improvement are expected in the field of lung cancer screening

Keywords： lung cancer low-dose computerized tomography early detection opportunities challenges